Paper Details

  1. Home
  2. Paper Details

A contemporary review of rearranged during transfection-selective inhibitors.

Author: LeeChung-Shien, LiangConnie, LiuAngel W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Selpercatinib and pralsetinib, two FDA-approved RET inhibitors, are effective in treating RET-mutated cancers, including non-small cell lung cancer and thyroid cancer. Both drugs showed promising efficacy, with objective response rates of 60% to 73%, and favorable safety profiles. Common adverse events included elevated liver function tests and hypertension.
Paper Details　
Original Abstract of the Article :
Label="OBJECTIVE" NlmCategory="OBJECTIVE">Rearranged during transfection genes are present in 1-2% of patients who have non-small cell lung cancer and 10-30% of patients with papillary thyroid cancer. The objective of this article is to review the current rearranged during transfection inhibitors in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552211040542

データ提供：米国国立医学図書館（NLM）

Exploring the Potential of Rearranged During Transfection (RET) Inhibitors

This review delves into the world of targeted cancer therapy, focusing on the development of rearranged during transfection (RET) inhibitors, a class of drugs designed to specifically target cancers driven by mutations in the RET gene. RET gene mutations are found in a significant percentage of patients with non-small cell lung cancer and papillary thyroid cancer. The review highlights the recent approval of two RET-selective inhibitors, selpercatinib and pralsetinib, for treating advanced or metastatic cancers harboring RET mutations. Both drugs have demonstrated promising efficacy in shrinking tumors and improving patient survival.

RET Inhibitors Offer Hope for RET-Mutated Cancers

The development of RET inhibitors represents a significant advance in targeted cancer therapy. These drugs offer a tailored approach for treating patients with RET-mutated cancers, potentially leading to better outcomes and reduced side effects compared to traditional chemotherapy.

Health and Lifestyle Implications

The availability of RET inhibitors opens up new possibilities for patients with RET-mutated cancers. These targeted therapies offer a more precise and potentially less toxic approach to treatment, improving patient quality of life and increasing the chances of successful cancer management.

Dr. Camel's Conclusion

This review highlights the remarkable progress in targeted cancer therapy. The development of RET inhibitors provides hope for patients with RET-mutated cancers, offering a personalized approach to treatment. As a researcher, I am inspired by the continued efforts to develop targeted therapies that effectively address specific cancer mutations. This is a testament to the power of scientific innovation in the fight against cancer.
Date :
  1. Date Completed 2021-12-13
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

34590525

DOI: Digital Object Identifier

10.1177/10781552211040542

Related Literature

Article Analysis
・Side Effects of selpercatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.